# US 2022/0016179 A1 · Amniotic Membrane Hydrogel and Methods of Making

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0016179 A1
- Document ID: US20220016179A1
- Status: Published application
- Kind: A1
- Application number: 17/186,278
- Filed: 2021-02-26
- Published: 2022-01-20
- Earliest claimed: 2012-09-10
- Assignees: Wake Forest University Health Sciences
- Applicants: Wake Forest University Health Sciences
- Inventors: Sean V. Murphy; Aleksander Skardal; Anthony Atala
- Web page: https://patentgrep.com/patent/US20220016179A1

## CPC

- A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61L 15/40: containing ingredients of undetermined constitution or reaction products thereof {, e.g. plant or animal extracts}
- A61L 26/0057: {Ingredients of undetermined constitution or reaction products thereof}
- A61L 26/0076: {Sprayable compositions}
- A61L 27/34: Macromolecular materials
- A61L 27/3604: {characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel}
- A61L 27/3683: {subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment}
- A61L 27/48: with macromolecular fillers
- A61L 27/52: Hydrogels or hydrocolloids
- C12N 5/0068: {General culture methods using substrates (for specific animal cell type C12N5/06)}
- A61L 2430/40: Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
- C12N 2533/92: Amnion; Decellularised dermis or mucosa
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides compositions and methods for wound healing and tissue regeneration. The compositions of the present invention comprise amniotic membrane of the placenta. In certain embodiments, the composition comprises amniotic membrane powder or solubilized amniotic membrane (SAM). In some aspects, the composition is cell-free and rich in cytokines, extracellular matrix proteins, and other components that improve tissue regeneration. In one aspect, the composition is a hydrogel scaffold that comprises amniotic membrane. The present invention reduces contraction and improves blood vessel development in regenerating tissue.

## Claims

### Claim 1

A method of inducing wound healing and tissue regeneration in a subject comprising contacting a wound at a treatment site on the subject with a composition comprising amniotic membrane and a scaffold comprising a hydrogel comprising a biopolymer and a synthetic polymer;
wherein the biopolymer comprises at least one biopolymer selected from the group consisting of hyaluronan and gelatin;
wherein the synthetic polymer comprises at least one synthetic polymer selected from the group consisting of (meth)acrylate-oligolactide-PEO-oligolactide-(meth)acrylate, poly(ethylene glycol) (PEO), poly(propylene glycol) (PPO), PEO-PPO-PEO copolymers, poly(phosphazene), poly(methacrylates), poly(N-vinylpyrrolidone), PLA-PEO-PLA copolymers, PLA-PEO-PLGA copolymers, PLGA-PEO-PLA copolymers, PLGA-PEO-PLGA copolymers, poly(ethylene imine), and poly(ethylene glycol) diacrylate, wherein PLA is polylactic acid and PLGA is poly(lactide-co-glycolide); and
wherein the amniotic membrane is mixed within and dispersed in the scaffold.

### Claim 2 (depends on 1)

The method of claim 1, wherein the biopolymer is thiolated.

### Claim 3 (depends on 1)

The method of claim 1, wherein the synthetic polymer is poly(ethyl glycol) diacrylate poly(ethylene glycol) diacrylate.

### Claim 4 (depends on 1)

The method of claim 1, wherein the scaffold comprises a photoinitiator.

### Claim 5 (depends on 4)

The method of claim 4, wherein the photoinitiator is 2-hydroxy-4′-hydroxyethoxy-2-methylpropiophenone.

### Claim 6 (depends on 1)

The method of claim 1, wherein the amniotic membrane is human amniotic membrane.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 8 (depends on 7)

The method of claim 7, wherein the subject is a human.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition is in the form of a solution, an ointment, a patch, a sponge, a mesh, an aerosol spray, or a foam.

### Claim 10 (depends on 1)

The method of claim 1, wherein the composition is disposed on the surface of a dressing.

### Claim 11 (depends on 1)

The method of claim 1, wherein the method further comprises administering UV light at the treatment site.

### Claim 12 (depends on 1)

The method of claim 1, wherein the treatment site is on an external surface of the subject.

### Claim 13 (depends on 1)

The method of claim 1, wherein the treatment site is on an internal surface of the subject.

### Claim 14

A method of dressing a wound in a subject comprising contacting the wound with a composition comprising amniotic membrane and a scaffold comprising a hydrogel comprising a biopolymer and a synthetic polymer;
wherein the biopolymer comprises at least one biopolymer selected from the group consisting of hyaluronan and gelatin;
wherein the synthetic polymer comprises at least one synthetic polymer selected from the group consisting of (meth)acrylate-oligolactide-PEO-oligolactide-(meth)acrylate, poly(ethylene glycol) (PEO), poly(propylene glycol) (PPO), PEO-PPO-PEO copolymers, poly(phosphazene), poly(methacrylates), poly(N-vinylpyrrolidone), PLA-PEO-PLA copolymers, PLA-PEO-PLGA copolymers, PLGA-PEO-PLA copolymers, PLGA-PEO-PLGA copolymers, poly(ethylene imine), and poly(ethylene glycol) diacrylate, wherein PLA is polylactic acid and PLGA is poly(lactide-co-glycolide); and
wherein the amniotic membrane is mixed within and dispersed in the scaffold.

### Claim 15 (depends on 14)

The method of claim 14, wherein the biopolymer is thiolated.

### Claim 16 (depends on 14)

The method of claim 14, wherein the synthetic polymer is poly(ethyl glycol) diacrylate poly(ethylene glycol) diacrylate.

### Claim 17 (depends on 14)

The method of claim 14, wherein the scaffold comprises a photoinitiator.

### Claim 18 (depends on 17)

The method of claim 17, wherein the photoinitiator is 2-hydroxy-4′-hydroxyethoxy-2-methylpropiophenone.

### Claim 19 (depends on 14)

The method of claim 14, wherein the amniotic membrane is human amniotic membrane.

### Claim 20 (depends on 14)

The method of claim 14, wherein the subject is a mammal.

### Claim at position 21

21-26. (canceled)
